Companies › UCB BIOSCIENCES
1 active drug program in 1 registered trial: 1 Phase 3; Psychiatry; next expected readout Feb 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| fenfluramine hydrochloride Serotonin 1d (5-HT1d) receptor agonist; Serotonin 2c (5-HT2c) receptor agonist; Sigma opioid receptor antagonist | HTR1D, HTR2C, SIGMAR1 | Phase 3 | Rett Syndrome | Feb 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07503444 | fenfluramine hydrochloride | Phase 3 | Rett Syndrome | Psychiatry | Feb 2029 |
Zogenix Exciva Technophage Boryung Pharmaceutical Tonix Pharmaceuticals Anavex Life Sciences Pentixapharm CSPC Ouyi Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.